ReviewFrontiers in immunology2019
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 44 citations in OpenAlex.
- Antigen-specific B cell response regulation by IL-10-producing tolerogenic dendritic cells.Science advances · 2025Article
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- Leveraging current insights on IL-10-producing dendritic cells for developing effective immunotherapeutic approaches.FEBS letters · 2025Review
- The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients.Frontiers in immunology · 2025Article
- Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4Frontiers in immunology · 2025Article
- Innate immune cellular therapeutics in transplantation.Frontiers in transplantation · 2023Article
- Liposomes loaded with vitamin D3 induce regulatory circuits in human dendritic cells.Frontiers in immunology · 2023Article
- T regulatory cells metabolism: The influence on functional properties and treatment potential.Frontiers in immunology · 2023Review
- Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia.Haemophilia : the official journal of the World Federation of Hemophilia · 2022Article
- Vitamin D3 Priming of Dendritic Cells Shifts Human Neutrophil-Dependent Th17 Cell Development to Regulatory T Cells.Frontiers in immunology · 2022Article
- Fluorine labelling of therapeutic human tolerogenic dendritic cells forFrontiers in immunology · 2022Article
- Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.Biomedicines · 2021Article
- FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity.Nature communications · 2021Article
- Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity.International journal of molecular sciences · 2021Review
- Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator.International journal of molecular sciences · 2021Article
- Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.Cellular & molecular immunology · 2021Review
- Tolerance induction in memory CD4 T cells is partial and reversible.Immunology · 2021Article
- Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients.Frontiers in immunology · 2021Review
- Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease.Frontiers in immunology · 2021Review
- Targeting DCs for Tolerance Induction: Don't Lose Sight of the Neutrophils.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.